Index -
P/E -
EPS (ttm) -0.37
Insider Own 1.29%
Shs Outstand 14.50M
Perf Week 11.62%
Market Cap 52.93M
Forward P/E -
EPS next Y -
Insider Trans 0.00%
Shs Float 14.31M
Perf Month 106.21%
Income -5.34M
PEG -
EPS next Q -
Inst Own 81.53%
Short Float 1.37%
Perf Quarter 131.01%
Sales 0.00M
P/S -
EPS this Y -
Inst Trans 11.34%
Short Ratio 0.14
Perf Half Y 79.80%
Book/sh 2.55
P/B 1.43
EPS next Y -
ROA -13.19%
Short Interest 0.20M
Perf Year 88.14%
Cash/sh 2.58
P/C 1.41
EPS next 5Y -
ROE -13.57%
52W Range 1.56 - 3.88
Perf YTD 114.71%
Dividend Est. -
P/FCF -
EPS past 5Y 48.59%
ROI -14.34%
52W High -5.93%
Beta 0.86
Dividend TTM -
Quick Ratio 59.01
Sales past 5Y 0.00%
Gross Margin -
52W Low 133.97%
ATR (14) 0.21
Dividend Ex-Date -
Current Ratio 59.01
EPS Y/Y TTM 46.28%
Oper. Margin 0.00%
RSI (14) 83.23
Volatility 6.57% 6.86%
Employees 5
Debt/Eq 0.01
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 17.00
Option/Short Yes / No
LT Debt/Eq 0.01
EPS Q/Q 7.85%
Payout -
Rel Volume 0.15
Prev Close 3.45
Sales Surprise -
EPS Surprise -
Sales Q/Q -
Earnings Oct 18 AMC
Avg Volume 1.42M
Price 3.65
SMA20 31.91%
SMA50 72.98%
SMA200 87.28%
Trades
Volume 209,294
Change 5.80%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-27-18 Initiated
Ascendiant Capital Markets
Buy
$2
Oct-09-13 Initiated
Dawson James
Buy
$3.75
Apr-03-24 02:30PM
12:00PM
07:30AM
Feb-01-24 04:35PM
Oct-18-23 04:25PM
04:25PM
Loading…
Jul-21-23 04:25PM
Jul-13-23 11:30AM
Apr-24-23 04:25PM
Feb-24-23 04:20PM
Feb-03-23 10:19AM
Dec-19-22 04:05PM
Nov-14-22 09:24AM
Oct-28-22 04:15PM
Aug-02-22 04:15PM
Jul-18-22 06:14AM
04:05PM
Loading…
Jun-21-22 04:05PM
May-05-22 04:15PM
May-02-22 04:15PM
Apr-18-22 04:30PM
Apr-05-22 01:35AM
Apr-01-22 07:09AM
Mar-31-22 04:15PM
Mar-14-22 04:15PM
Mar-07-22 04:30PM
Feb-08-22 04:21AM
Jan-04-22 08:30AM
Dec-02-21 08:30AM
Nov-20-21 07:01AM
Nov-09-21 04:15PM
Nov-02-21 04:15PM
07:03AM
Loading…
Oct-29-21 07:03AM
06:26AM
Oct-28-21 04:30PM
Sep-16-21 08:30AM
Aug-16-21 08:05AM
Aug-12-21 01:15AM
Aug-09-21 08:00AM
Aug-04-21 04:15PM
Jul-28-21 08:00AM
Jul-13-21 08:00AM
Jul-09-21 08:00AM
Jul-08-21 11:20AM
Jul-07-21 08:00AM
Jun-23-21 09:35AM
May-11-21 04:15PM
May-05-21 04:05PM
May-03-21 04:30PM
Mar-18-21 04:30PM
Feb-13-21 01:09AM
Dec-15-20 08:30AM
Dec-09-20 05:40PM
Nov-23-20 12:28PM
08:30AM
Nov-02-20 08:30AM
Oct-07-20 08:30AM
Oct-05-20 04:30PM
Sep-21-20 08:00AM
Aug-17-20 08:49AM
Aug-12-20 08:00AM
Aug-05-20 04:15PM
Jul-07-20 08:30AM
Jun-03-20 09:56AM
09:56AM
Jun-01-20 08:20AM
May-29-20 12:24PM
09:59AM
May-28-20 04:19PM
(Investor's Business Daily) +386.33%
12:14PM
(Investor's Business Daily)
10:27AM
08:00AM
May-07-20 08:30AM
May-06-20 04:30PM
Feb-18-20 04:30PM
Feb-01-20 08:31AM
Nov-06-19 04:10PM
Nov-03-19 08:47AM
Sep-12-19 08:30AM
Sep-11-19 08:30AM
Sep-04-19 01:37PM
Aug-21-19 09:49AM
Aug-01-19 04:30PM
Jun-04-19 07:09AM
May-13-19 09:00AM
May-08-19 04:30PM
May-01-19 08:30AM
Apr-23-19 08:30AM
Mar-18-19 08:30AM
Mar-06-19 08:00AM
Feb-27-19 04:15PM
Feb-20-19 07:30AM
Jan-16-19 08:30AM
Dec-26-18 11:47AM
Dec-20-18 04:01PM
Nov-14-18 04:30PM
Nov-12-18 08:30AM
Nov-05-18 08:30AM
Oct-10-18 04:16PM
(American City Business Journals) -5.43%
Oct-02-18 08:00AM
Sep-18-18 08:30AM
Aug-09-18 04:15PM
ARCA biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of targeted therapies for cardiovascular diseases. The firm focuses on the cardiovascular pathophysiology, molecular genetics, and clinical development. Its product candidate, Gencaro is a pharmacologic beta-blocker and mild vasodilator, which is developed for the treatment of chronic heart failure and other indications. The company was founded by Michael R. Bristow and Christopher David Ozeroff in 1992 and is headquartered in Westminster, CO.
Index RUT
P/E -
EPS (ttm) -0.69
Insider Own 28.22%
Shs Outstand 60.35M
Perf Week 0.08%
Market Cap 4.23B
Forward P/E -
EPS next Y -1.96
Insider Trans -16.24%
Shs Float 47.05M
Perf Month 64.08%
Income -32.18M
PEG -
EPS next Q -0.43
Inst Own 68.54%
Short Float 11.23%
Perf Quarter 231.37%
Sales 58.88M
P/S 71.86
EPS this Y -174.80%
Inst Trans 37.61%
Short Ratio 2.38
Perf Half Y 550.71%
Book/sh 5.43
P/B 11.88
EPS next Y -11.44%
ROA -9.63%
Short Interest 5.28M
Perf Year 801.54%
Cash/sh 4.99
P/C 12.92
EPS next 5Y -
ROE -12.69%
52W Range 6.71 - 64.58
Perf YTD 238.67%
Dividend Est. -
P/FCF -
EPS past 5Y 24.56%
ROI -9.55%
52W High -0.05%
Beta 0.95
Dividend TTM -
Quick Ratio 7.86
Sales past 5Y 171.70%
Gross Margin 99.02%
52W Low 862.00%
ATR (14) 2.38
Dividend Ex-Date -
Current Ratio 7.86
EPS Y/Y TTM 58.73%
Oper. Margin -75.16%
RSI (14) 83.39
Volatility 0.20% 5.59%
Employees 142
Debt/Eq 0.03
Sales Y/Y TTM 95.84%
Profit Margin -54.66%
Recom 2.75
Target Price 65.00
Option/Short Yes / Yes
LT Debt/Eq 0.03
EPS Q/Q 124.03%
Payout -
Rel Volume 1.40
Prev Close 64.58
Sales Surprise 238.91%
EPS Surprise 145.45%
Sales Q/Q 1011.42%
Earnings Mar 18 AMC
Avg Volume 2.22M
Price 64.55
SMA20 31.56%
SMA50 59.19%
SMA200 203.95%
Trades
Volume 3,104,151
Change -0.05%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-09-24 Initiated
Guggenheim
Buy
$55
Feb-15-24 Initiated
Wolfe Research
Outperform
$44
Oct-18-23 Initiated
Berenberg
Buy
$18
Oct-17-23 Initiated
Berenberg
Buy
$18
Oct-05-23 Initiated
RBC Capital Mkts
Outperform
$19
Jun-26-23 Resumed
Oppenheimer
Outperform
$14
Jan-19-23 Initiated
Morgan Stanley
Overweight
$17
Nov-21-22 Initiated
SVB Leerink
Outperform
$15
Dec-21-20 Initiated
H.C. Wainwright
Buy
$21
Aug-26-20 Initiated
Cowen
Outperform
Apr-18-24 08:30AM
Apr-15-24 03:43PM
09:15AM
Apr-13-24 05:29AM
Apr-12-24 12:36PM
10:55AM
Loading…
10:55AM
(The Wall Street Journal)
Apr-11-24 04:43PM
04:29PM
04:18PM
(Investor's Business Daily)
01:59PM
(The Wall Street Journal)
01:07PM
11:58AM
11:03AM
09:47AM
09:47AM
09:39AM
Loading…
09:39AM
07:34AM
Apr-10-24 10:34PM
07:05PM
05:47PM
(The Wall Street Journal)
05:14PM
(Investor's Business Daily)
04:19PM
04:16PM
04:15PM
04:06PM
04:01PM
01:34PM
Apr-09-24 09:23AM
Apr-01-24 09:00AM
Mar-21-24 07:45AM
04:30PM
Loading…
Mar-20-24 04:30PM
Mar-19-24 08:32AM
06:48AM
(Thomson Reuters StreetEvents)
Mar-18-24 08:53PM
07:25PM
05:31PM
04:05PM
Mar-14-24 08:38AM
Mar-11-24 10:00AM
Mar-07-24 04:30PM
Feb-26-24 04:30PM
Feb-01-24 04:30PM
Dec-21-23 04:15PM
Dec-19-23 09:50AM
Dec-18-23 04:30PM
Dec-06-23 09:55AM
Nov-29-23 09:40AM
Nov-20-23 04:30PM
09:55AM
Nov-17-23 07:44PM
Nov-15-23 09:00AM
Nov-14-23 08:55PM
04:15PM
03:57PM
Nov-13-23 09:00AM
Nov-06-23 09:41PM
06:00AM
Nov-03-23 09:00AM
Nov-02-23 09:00AM
Oct-30-23 10:01AM
09:00AM
Oct-27-23 09:40AM
Oct-23-23 12:00PM
Oct-13-23 09:05AM
Oct-12-23 12:13PM
Oct-11-23 10:15AM
Oct-09-23 11:10AM
Oct-06-23 09:55AM
09:24AM
Oct-04-23 08:17AM
08:00AM
Oct-03-23 07:43AM
Sep-18-23 08:52AM
Sep-12-23 08:30AM
Sep-08-23 09:40AM
Sep-05-23 04:30PM
08:30AM
Aug-30-23 04:30PM
Aug-24-23 08:50AM
Aug-22-23 04:30PM
Aug-17-23 09:55AM
Aug-14-23 04:15PM
Jul-23-23 10:25AM
Jun-22-23 07:43AM
Jun-20-23 07:14PM
May-19-23 04:30PM
May-11-23 04:15PM
May-05-23 07:04AM
May-01-23 04:30PM
Mar-27-23 09:16AM
07:08AM
Mar-24-23 10:02AM
(Thomson Reuters StreetEvents) -8.25%
Mar-23-23 05:35PM
04:05PM
Mar-20-23 04:30PM
Mar-16-23 05:30PM
Mar-15-23 04:30PM
Feb-28-23 04:33PM
Feb-13-23 05:16AM
Feb-09-23 04:45PM
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company, which focusses on discovering and developing innovative, protein-based immunotherapies to treat autoimmune and inflammatory diseases. Its product pipeline includes inflammatory diseases, immuno-oncology, and engineered cellular therapies. The company was founded in March 2007 and is headquartered in Seattle, WA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Rickey James Paul See Remarks Jan 26 '24 Option Exercise 8.30 117,764 977,844 73,764 Jan 29 07:04 PM Rickey James Paul See Remarks Jan 26 '24 Sale 23.32 117,764 2,745,830 0 Jan 29 07:04 PM Rickey James Paul See Remarks Jan 25 '24 Option Exercise 6.51 236 1,536 236 Jan 29 07:04 PM Rickey James Paul See Remarks Jan 25 '24 Sale 22.00 236 5,192 0 Jan 29 07:04 PM GOLD MITCHELL Executive Chairman and CEO Dec 28 '23 Option Exercise 12.74 74,441 948,378 2,675,421 Dec 29 07:32 PM GOLD MITCHELL Executive Chairman and CEO Dec 28 '23 Option Exercise 0.65 1,016 660 1,016 Dec 29 07:32 PM ORBIMED ADVISORS LLC Director Dec 28 '23 Sale 18.35 1,364,849 25,049,034 264,315 Dec 29 04:18 PM Thompson Peter A. Director Dec 28 '23 Sale 18.35 1,364,849 25,049,034 264,315 Dec 29 04:20 PM GOLD MITCHELL Executive Chairman and CEO Dec 28 '23 Sale 20.04 1,016 20,362 0 Dec 29 07:32 PM GOLD MITCHELL Executive Chairman and CEO Dec 27 '23 Option Exercise 0.65 29,573 19,222 29,573 Dec 27 09:07 PM ORBIMED ADVISORS LLC Director Dec 27 '23 Sale 19.96 181,498 3,622,700 406,609 Dec 29 04:18 PM Thompson Peter A. Director Dec 27 '23 Sale 19.96 181,498 3,622,700 406,609 Dec 29 04:20 PM GOLD MITCHELL Executive Chairman and CEO Dec 27 '23 Sale 20.04 29,573 592,717 0 Dec 27 09:07 PM GOLD MITCHELL Executive Chairman and CEO Dec 26 '23 Option Exercise 0.63 24,486 15,436 24,486 Dec 27 09:07 PM GOLD MITCHELL Executive Chairman and CEO Dec 26 '23 Sale 20.22 24,486 495,217 0 Dec 27 09:07 PM GOLD MITCHELL Executive Chairman and CEO Dec 22 '23 Option Exercise 0.45 37,825 17,021 37,825 Dec 27 09:07 PM GOLD MITCHELL Executive Chairman and CEO Dec 22 '23 Sale 20.43 37,825 772,595 0 Dec 27 09:07 PM Rickey James Paul See Remarks Dec 19 '23 Option Exercise 5.02 15,213 76,369 15,213 Dec 21 07:35 PM GOLD MITCHELL Executive Chairman and CEO Dec 19 '23 Option Exercise 0.45 2,402 1,081 2,402 Dec 21 07:34 PM Rickey James Paul See Remarks Dec 19 '23 Sale 19.21 15,213 292,222 0 Dec 21 07:35 PM GOLD MITCHELL Executive Chairman and CEO Dec 19 '23 Sale 20.01 2,402 48,064 0 Dec 21 07:34 PM Rickey James Paul See Remarks Dec 18 '23 Option Exercise 5.02 1,800 9,036 1,800 Dec 18 09:20 PM Rickey James Paul See Remarks Dec 18 '23 Sale 19.00 1,800 34,203 0 Dec 18 09:20 PM Rickey James Paul See Remarks Dec 15 '23 Option Exercise 5.02 45,387 227,843 45,387 Dec 18 09:20 PM Rickey James Paul See Remarks Dec 15 '23 Sale 19.09 45,387 866,383 0 Dec 18 09:20 PM Rickey James Paul See Remarks Dec 14 '23 Option Exercise 5.02 11,600 58,232 11,600 Dec 18 09:20 PM Rickey James Paul See Remarks Dec 14 '23 Sale 19.00 11,600 220,406 0 Dec 18 09:20 PM GOLD MITCHELL Executive Chairman and CEO Dec 12 '23 Option Exercise 0.45 8,613 3,876 8,613 Dec 12 09:02 PM GOLD MITCHELL Executive Chairman and CEO Dec 12 '23 Sale 17.32 41,063 711,026 0 Dec 12 09:02 PM GOLD MITCHELL Executive Chairman and CEO Dec 11 '23 Sale 17.26 68,870 1,189,027 32,450 Dec 12 09:02 PM GOLD MITCHELL Executive Chairman and CEO Dec 08 '23 Sale 17.08 8,067 137,784 101,320 Dec 12 09:02 PM Rickey James Paul See Remarks Dec 06 '23 Option Exercise 3.23 6,446 20,821 6,446 Dec 06 07:31 PM Rickey James Paul See Remarks Dec 06 '23 Sale 16.08 6,446 103,650 0 Dec 06 07:31 PM Rickey James Paul See Remarks Dec 05 '23 Option Exercise 3.23 418 1,350 418 Dec 06 07:31 PM Rickey James Paul See Remarks Dec 05 '23 Sale 16.01 418 6,694 0 Dec 06 07:31 PM Rickey James Paul See Remarks Dec 04 '23 Option Exercise 3.23 63,947 206,549 63,947 Dec 06 07:31 PM Rickey James Paul See Remarks Dec 04 '23 Sale 16.06 63,947 1,026,887 0 Dec 06 07:31 PM Rickey James Paul See Remarks Nov 30 '23 Option Exercise 3.23 700 2,261 700 Dec 01 05:00 PM Rickey James Paul See Remarks Nov 30 '23 Sale 16.00 700 11,200 0 Dec 01 05:00 PM Rickey James Paul See Remarks Nov 06 '23 Option Exercise 3.23 10,989 35,494 18,003 Nov 08 05:20 PM Rickey James Paul See Remarks Nov 06 '23 Sale 16.03 18,003 288,554 0 Nov 08 05:20 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite